Reinforcement Learning and Obsessive-compulsive Disorder: Exploring the Role of the Orbitofrontal Cortex

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorFundacao Champalimaud

About this trial

Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition affecting 1-3% of the population. Typically, symptoms start in adolescence or early adulthood, are time-consuming, and have a significant impact on quality of life. However, first-line approved treatments, based on a combination of pharmacotherapy and psychotherapy, are ineffective in at least 50% of cases. Since the pathophysiology of OCD remains largely unknown, it is expected that a better understanding of the biological mechanisms of OCD would contribute to improved strategies for treatment of the disorder.

Current neurobiological models for OCD highlight the role of corticostriatal dysfunction and hyperactivity of the orbitofrontal cortex (OFC), a part of the prefrontal cortex. Indeed, the lateral OFC plays a crucial role in controlling transitions between automatic, repetitive stimulus-response driven behaviors, and behaviors that reflect the acquisition, by the agent, of a predictive model of the consequences of each action. Previous studies have suggested that the ability to operate this transition is compromised in OCD and may be objectively measured using specifically designed Reinforcement Learning (RL) tasks. Furthermore, growing evidence has suggested that OCD may be associated with systemic immune dysfunction, as has been shown in other common neuropsychiatric conditions, such as depressive disorders. Indeed, there is evidence to support OCD-like symptoms occurring acutely in children after streptococcal infection. These findings have raised the hypothesis that vulnerable individuals exposed to pro-inflammatory early-life environmental risk factors, such as infections and childhood adversity, may suffer neuroinflammatory-induced dysfunction in corticostriatal pathways, increasing the risk of OCD psychopathology.

In this case-control study, the investigators propose an integrative approach to address how structural, functional, and metabolic brain changes involving the corticostriatal circuit correlate with performance in an RL task, as well as with peripheral blood markers of immune dysfunction and associated environmental risk factors such as infection and childhood trauma. Furthermore, since neuromodulation of the prefrontal cortex, using repetitive transcranial magnetic stimulation (rTMS), has recently received FDA clearance for adjunctive treatment in patients with OCD, these associations will be further explored in patients treated with this method. Indeed, in patients with OCD enrolled in the study upon referral to the rTMS Programme for OCD at the Champalimaud Clinical Centre, a follow-up visit will be conducted after the end of treatment (30 sessions of excitatory rTMS over the medial prefrontal cortex). In this subgroup of participants with longitudinal assessment, we will measure change in study parameters and the associations between such change and the clinical effects of treatment, as well as prediction of treatment effects according to baseline assessments.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Exclusively for the OCD group: established diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria;

Exclusively for the control group: does not meet DSM criteria for any of the psychiatric diagnoses screened by the Mini International Neuropsychiatric Interview;

Age between 18 and 65 years-old;

Fluent Portuguese or English speaker.

Disqualifiers

Any acute medical illness;

Substance abuse or dependence;

Pregnancy;

Dementia;

Trial population

Participants in this study will be adults, aged 18 to 65 years, that will be recruited either for the clinical or control group. The clinical population will include individuals with OCD diagnosis, according to the following inclusion criteria. The two groups will be matched by age and sex.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

230 Participants
are grouped into 2 trial groups
Group A: Obsessive-compulsive disorder group
Group B: Healthy subjects group

Trial outcomes

Primary outcomes

1

Concentration of high sensitivity C Reactive Protein (hsCRP).

Serum concentration of hsCRP, expressed in mg/dL, as measured by enzyme-linked immunosorbent assay (ELISA).

Time frame
Baseline.
2

Seropositivity for Group A Streptococcus (GAS).

Number of participants who are seropositive for GAS measured by anti-streptolysin O (ASO) antibodies (IgG).

Time frame
Baseline.
3

Basal ganglia and orbito-frontal cortex (OFC) volume.

Volume of basal ganglia structures (e.g. caudate, putamen and globus pallidus) and the OFC, in cubic milimeters.

Time frame
Baseline.
4

Exposure to childhood trauma as measured by the Childhood Trauma Questionnaire (CTQ).

Exposure to childhood trauma measured by the CTQ. The total score varies between 25 and 125, providing an overall measure of the exposure to childhood trauma, with higher scores representing exposure to more (and more severe) traumatic events.

Time frame
Baseline.

Secondary outcomes

1

Peripheral concentration of cytokines.

Plasmatic concentration of cytokines (interferon gamma (IFN-γ), tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17 and IL-23), expressed In pg/mL, as measured by ELISA.

Time frame
Baseline
2

Peripheral concentration of transforming growth factor (TGF)-β.

Plasmatic concentration of TGF-β, expressed in pM, as measured by ELISA.

Time frame
Baseline
3

Presence of auto-antibodies.

Number of participants positive for auto-antibodies such as anti-basal ganglia (ABGA), anti-nuclear (ANA), and anti-thyroid antibodies.

Time frame
Baseline
4

Seropositivity for Toxoplasma gondii, Cytomegalovirus (CMV), Herpes simplex virus (HSV1 and HSV2).

Number of participants who are seropositive for IgG Toxoplasma gondii, CMV, HSV1 and HSV2 antibodies.

Time frame
Baseline

Other outcomes

1

Gene expression of peripheral cytokines.

Genetic expression of peripheral cytokines (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-23 and TGF-β), expressed in cycle thresholds (CT), as measured by quantitative Real-Time Polymerase Chain Reaction (RT-PCR).

Time frame
Baseline
2

Functional connectivity pattern supported in lesional OCD neuroanatomy.

Voxel-wise functional connectivity of the regions-of-interest extracted from lesional network mapping analyses of cases with secondary OCD.

Time frame
Baseline
3

Measurement of Mean Kurtosis (MK) in the brain white matter.

Voxel-wise MK obtained from DWI.

Time frame
Baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.